Journal
BIOMEDICINES
Volume 10, Issue 7, Pages -Publisher
MDPI
DOI: 10.3390/biomedicines10071641
Keywords
COVID-19; vaccination; Pfizer; BioNTech; BNT162b2; Moderna; mRNA-1273; AstraZeneca; AZD1222; hypersensitivity
Ask authors/readers for more resources
This article reviews the structure of SARS-CoV-2 and discusses the safety profiles of vaccines such as BNT162b2, mRNA-1273, and AZD1222. It aims to provide an understanding of the possible immune mechanisms behind hypersensitivity reactions related to COVID-19 vaccination.
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes coronavirus disease 2019 (COVID-19), is a member of the genus Betacoronavirus. This virus was first detected in December 2019, and the situation quickly escalated to cause a global pandemic within a few months. COVID-19 had caused more than 5.5 million deaths as of January 2022. Hence, the urgency of effective vaccination contributed to the fastest rate of vaccine development seen to date (i.e., within 1.5 years). Despite reports of good vaccine efficacy without severe systemic reactions at the clinical trial stage, hypersensitivity reactions have been reported following worldwide vaccination campaigns. We provide a brief review regarding the structure of SARS-CoV-2. We also review the most acceptable types of vaccines in terms of safety profiles, namely the BNT162b2, mRNA-1273, and AZD1222 vaccines. This review aims to facilitate an understanding of the possible immune mechanisms regarding COVID-19-vaccination-related hypersensitivity reactions, such as thrombosis and thrombocytopenia, cutaneous adverse reactions, myocarditis, and perimyocarditis.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available